ADDITIONAL COSTS RELATED TO ORAL JANUS KINASE INHIBITOR USE IN ATOPIC DERMATITIS

被引：0
|
作者：
Robinson, Stephen [1 ]
Kallala, Rami [1 ]
Jo-Hansen, Christian Dall [2 ]
Panek, Malgorzata [3 ]
Nikodem, Mateusz [3 ]
Chudzik, Kamila [3 ]
Damentko, Magdalena [4 ]
Brandi, Henrik [5 ]
机构：
[1] Leo Pharma UK, Maidenhead, Berks, England
[2] Leo Pharma AS, Copenhagen, Denmark
[3] Putnam PHMR, Krakow, Poland
[4] Putnam PHMR, Warsaw, Poland
[5] Leopharma AS, Copenhagen, Denmark
来源：
ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P5.6
引用
收藏
页码：33 / 34
页数：2
相关论文
共 50 条
  • [41] Predictors of maintenance of response in patients with moderate-to-severe atopic dermatitis after interruption of the oral Janus kinase 1-selective inhibitor abrocitinib
    Gooderham, M. J.
    Girolomoni, G.
    Moore, J. O.
    Silverberg, J. I.
    Curto, M.
    Zhang, W.
    DiBonaventura, M.
    Valdez, H.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E106 - E106
  • [42] Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis
    Verstovsek, Srdan
    POSTGRADUATE MEDICINE, 2013, 125 (01) : 128 - 135
  • [43] Remission of Severe Eyelid Dermatitis With a Topical Janus Kinase Inhibitor
    Peterson, Danielle
    King, Brett
    DERMATITIS, 2021, 32 (1S) : E98 - E99
  • [44] Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
    Kostovic, Kresimir
    Gulin, Sandra J.
    Mokos, Zrinka B.
    Ceovic, Romana
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (11) : 1158 - 1167
  • [45] Baricitinib, an oral, reversible Janus kinase-1 and-2 inhibitor, for atopic dermatitis: Head and neck response from BREEZE-AD5
    Bissonnette, Robert
    Korman, Neil
    Lockshin, Benjamin
    Lu, Na
    Chen, Yun-Fei
    Goldblum, Orin
    Rueda, Jose
    Poulin, Yves
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB91 - AB91
  • [46] Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis
    Nakagawa, Hidemi
    Nemoto, Osamu
    Igarashi, Atsuyuki
    Saeki, Hidehisa
    Murata, Ryusei
    Kaino, Hironobu
    Nagata, Takeshi
    JOURNAL OF DERMATOLOGY, 2020, 47 (02): : 114 - 120
  • [47] Kinetic-Pharmacodynamic Model of Platelet Time Course in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib
    Soto, Elena
    Banfield, Christopher
    Gupta, Pankaj
    Peterson, Mark C.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2020, 9 (10): : 553 - 560
  • [48] Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial (vol 155, 1371, 2019)
    Gooderham, M. J.
    Forman, S. B.
    Bissonnette, R.
    JAMA DERMATOLOGY, 2020, 156 (01) : 104 - 104
  • [49] Tofacitinib: a new oral Janus kinase inhibitor for psoriasis
    Gimenez-Arnau, A. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (01) : 13 - 14
  • [50] Randomized, blind, placebo-controlled clinical trial on the clinical efficacy of oclacitinib, an oral janus kinase inhibitor, in a canine model of spontaneously occurring atopic dermatitis
    Marsella, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (08) : B6 - B6
12345